APTO - Aptose Biosciences updates on clinical trial progress

Announcing its Q4 2020 results, Aptose Biosciences ([[APTO]] +80.1%) shared the latest updates on its clinical development program for luxeptinib undergoing two Phase 1 a/b studies in R/R acute myeloid leukemia and B-cell Malignancies.For luxeptinib in R/R acute myeloid leukemia, Aptose completed the 450 mg bid dose cohort and has escalated to the 600 mg bid dose. Luxeptinib has demonstrated ‘encouraging’ anti-leukemic activity at the first dose level of 450mg bid.A patient remains on the study, with a complete response and having no apparent safety signals, the company said.For luxeptinib in B-cell malignancies including chronic lymphocytic leukemia (“CLL”) and non-Hodgkin’s lymphomas (“NHL”), Aptose is treating patients at the fifth dose level of 750 mg BID in the dose-escalation study.“To date, Aptose has observed on-target activity, including inhibition of multiple oncogenic driver kinases, lymphocytosis, and tumor reductions,” the company said in the statement adding that the updated data of both trials

For further details see:

Aptose Biosciences updates on clinical trial progress